Hedge Funds Make Big After Regeneron $REGN Gets FDA OK for Eylea

Regeneron Pharmaceuticals Inc.’s (REGN) shares rose 13.73% in trading on Monday after U.S. regulators approved its “drug Eylea to treat a leading cause of blindness in the elderly, handing the company a second product to sell and inserting a market challenger to Roche Holding AG (RHHBY, ROG.VX),” reports the Wall Street Journal. “Shares in Regeneron were halted before the news. The stock closed Friday down 2.6% at $49.81.” REGN was trading at $56.65 at 1:40pm EST Monday.

Leonard S. Schleifer, Regeneron Chief Executive, said Friday that REGN, “planned to make Eylea available to patients ‘within the next few days’ after the U.S. Food and Drug Administration approved it to treat wet age-related macular degeneration.”

Chuck Royce

The following hedge funds made the most on the news:

1. Qvt Financial – Daniel Gold: Gained $2.1 million

2. Royce & Associates – Chuck Royce: Gained $684,000

3. Orbimed Advisors – Samuel Isaly: Gained $527,000

4. Highbridge Capital Management – Glenn Russell Dubin: Gained $372,000

5. D E Shaw – D. E. Shaw: Gained $236,000

6. Hbk Investments – David Costen Haley: Gained $196,000

7. Sac Capital Advisors – Steven Cohen: Gained $107,000

8. Millennium Management – Israel Englander: Gained $90,000

9. Aqr Capital Management – Cliff Asness: Gained $44,000

10. Citadel Investment Group – Ken Griffin: Gained $3,300

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in REGN since the end of June. We did not take into account their option positions.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!